A new report from World Health Organization (WHO) estimates that broad use of improved seasonal influenza vaccines could prevent 6.6 to 18 billion additional influenza cases, 2.3 to 6.2 million deaths, and 21 to 57 million disability-adjusted life years (DALYs) globally between 2025 and 2050.
The Full Value of Improved Influenza Vaccine Assessment, published in January, evaluates the health, economic, and policy impacts of next-generation influenza vaccines and identify barriers to their uptake. More effective and long-lasting flu vaccines would be an economic boon for most WHO member states, the report said.
Cost savings for low- and middle-income countries
The analysis shows that overall, the market size for seasonal influenza vaccines is large and will remain so for the foreseeable future, which ensures the commercial viability of the vaccines. Moreover, seasonal flu vaccines can be cost-saving or cost-effective in many countries when priced appropriately.
These vaccines have the potential to reduce the global burden of influenza significantly.
“By addressing key challenges in vaccine development, decision-making, market demand, health and economic impact, financial viability, and implementation, these vaccines have the potential to reduce the global burden of influenza significantly and to improve health outcomes, particularly in low- and middle-income countries,” the report said.